Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
lnternational Archives of Allergy and Applied Immunology Editors-in-Chief: R. R. A. Coor,os, Cambridge; P. Keu6s, Helsingborg; L. M. LTcHTENsrBN, Baltimore, Md.; F. Mn-cnou, Buffalo, N. Y.; Z. TnNre, Basel; G. B. Wesr, Epsom Publishers: S. Kencrn, Basel REPRDTT (Printed in Switzerland) Int. Archs Allergy appl. Immun. 54: 422-427 (lW7) Suppression of Cell-Mediated Immunity by Metronidazole D.I. Grove, A. A. F. Mahmoud and K. S.Warren Division of Geographic Medicine, Department of Medicine, Case Western Reserve University and University Hospitals, Cleveland, Ohio Abstract. Metronidazole administered orally in doses of 20 and 200 mg/kg daily suppressed granuloma formation around Schistosoma mansoni eggs which were injected intravenously and lodged in the pulmonary rnicrovasculature of mice. The same doses did not suppress granuloma formation in animals which had previously been sensitized to the eggs. Nonspecific granulomatous inflammation around divinyl benzene copolymer beads was unaJfected by the drug. In a daily dose of 20 mglkg, metronidazole inhibited delayed footpad reactions to soluble schistosonne egg antigen, but 200 mgikg on alternate days failed to suppress skin allograft rejection. The drug appears to suppress selectively some aspects of cell-mediated immunity. Both metronidazole and niridazole have been reported to be effective for the treatment of guinea worm (Dracunculus medinesrs) infection, apparently acting by suppression of inflammation thus facilitating the removal of long segments of the worm [1, 3, B]. Recently, it was shown that niridazole suppresses cell-mediated immunological reactions including granuloma formation around eggs of Schistosoma mansoni, deIayed footpad swelling following the injection of soluble schistosome egg antigens and skin allograft rejection [5, 6]. These observations suggested the possibility that metronidazole may also have imrnunosuppressive properties. The present studies were undertaken, therefore, to assess the effect of this drug on the following cell-mediated immu- nological reactions: granuloma formation around S. mansoni eggs, nonspecific inflammation around divinyl benzene copolymer beads, delayed hypersensitivity footpad reactions and skin allograft rejection. Materials and Methods Metronidazole was obtained from Searle (San Juan, Puerto Rico). Different concentration of the drug were suspended in distilled water and 0.4 ml was administered to mice orally through a blunt tip 16-gauge needle. Metronidazole is usually well absorbed after oral administration [9]. Granuloma Formation around S. mansoni Eggs Schistosome eggs were obtained from the livers of mice 8 weeks after exposure to 200 cercariae of a Puerto Rican strain of S. mansoni using the 423 Grove/MahmoudflVarren method described by Moore et al. U\. Young fernale Swiss albino mice (Flow Laboratories, Dubiin, Virginia), 20-22 e in weight, were given 1,500 eggs intravenously via a tail vein. Two groups of mice were used: unsensitized and sensitized, sensitization being achieved by intraperitoneal injection of 1,500 eggs 14 days prior to the intravenous injection of eggs. Administration of metronidazole was begun on the day of intravenous egg injection. Eight days after intravenous egg injection in the case of sensitized mice, and 16 days for unsensitized animals, groups of mice were killed, the iungs removed, sectioned and stained as previously described [6]. Lungs were removed at these times as they have been shown to be the points of maximal inflammation around eggs in sensitized and unsensitized animals, respectively [15]. Mea- surement of the area of granulomatous inflammaeggs was performed with a zr-MC par- difference in thickness at 24 h between the two experimental footpads of each animal was taken as the net swelling. Skin Allogralting Adult female BALB/c J and C57BL/6 J mice were obtained from Jackson Laboratories (Bar Harbor, Me.). All mice were maintained on a diet of commercial food pellets and water ad libitum' Grafting of C57BL|6 I skin on to BALB/c J mice was performed and graft survival scored as previously described [6]' Groups of mice were treated with either 20 mg/kg metronidazole daily or 200 mg/kg on alternate days beginning 1 day before grafting. Results tion around ticle measurement computer system (Millipore Corporation, Bedford, Mass.) as previously described 16l. Ten lesions from each of B or 9 animals were measured, the results tested statistically by analysis of variance [11] and presented in the tables as the mean value and range representing 950/o of the observed values. G rantdoma F ormation around Divinyl Divinyl benzene copolymer plastic beads (BioRad, Richmond, Calif.) were prepared to a size equivalent to schistosome eggs by screening through a 70-mesh steel sieve and were three times with normal saline [4]. Groups of mice washed were given either 200 or 20 mg/kg daily for 3 days, beginning 1 day before the injection of in 0.5 The effect E gg Gr anuloma of daily administration of varying doses of metronidazole on the area of granulomatous inflammation in unsensitized mice 16 days after intravenous egg injection is shown in table I and figure 1' There was increasing suppression of inflammation with increasing doses of metronida- Benz.ene CopolYmer Beads 3,000 beads suspended Schistosome ml physiological sa- line via the tail vein. Lungs were removed at 48 h' the time of the peak inflammatory reaction [4] and measured as described above. Delayed Footpad Swelling zole, the results being statistically significant in the animals which received 200 (p<0.01) or z\mglkg (p(0.05), but not in those which were given 2.0 or O.Zmglkg daily' A single dose of metronidazole 20A mg/kg on the day of egg injection did not suppress the granulornatous reaction (table I). Metronidazole 200 mg/kg daily had no effect on the mean granuloma size 8 days after intravenous egg injection in sensitized mice, the mearl area of inflammation being (13,000-58,000 ,amz) compared Mice were sensitized by the intraperitoneal injection of 2,000 S. mansoni eggs and half were 35,400 given 20 mg/kg metronidazole daily from that day' control mice. In order to determine whether this failure to suppress inflammation in sensitized mice was due to the fact that metronidazole was administered for only 8 days (cf' L6 The effect of the drug on footpad swelling was tested on the 14th day by injection of soluble schistosome egg antigen equal to 10 pg protein in ml as described [2], in one rear footpad, and phosphate-buffered saline in the other. The mean 0.03 pcmz with 39,500 pm2 (l-9,000-60,000 pm') in Grove/Mahmoud/Warren 424 intravenous inTable I. Effect of different doses of metronidazole on granuloma formation 16 days after the given daily for 16 was metronidazole mice; of jection of S. msnsoni eggs into the pulmonary microvasculature days Control Metronidazole, Metronidazole, Metronidazole, Metronidazole, Metronidazole, n t 200 mg/kg dailY 20 mg/ks dailY 2 mg/kg daiiY 0.2 mg/kg dailY 200 mg/kg once areaa Number Mean prfiz 9 16,000 8 9 4,500 9,100 I 9,700 8 16,300 8 17,500 Range, Pm2 5,600-26,700 700-8,300 700-21,500 1,700-23,800 1,900-33,300 5,000-30,100 Probabilityb <0.01 <0.05 NS NS NS Egg included. Analysis of variance' mice were given either 20 or 200 mg/kg me- -E tronidazole daily for 16 days. 1,500 eggs were injected intravenously on the 8th day of drug administration and the lungs removed on the 16th day. Again, no significant differences were found, the mean area of inflammation being 30,800 tr,lm2 (6,85062,000 ptmz) in mice given 20 mglkg metronidazole and 30,000 prm2 (7,50060,000 pmz) in those given 200 mg/kg sco d o 400 e 6 c .9 0 soo d t] ?nn .q metronidazole, E Po roo L9 cd _s in 0.2 2 20 2C0 Metronidazote) mg/kg daiiY Fig. 1. Effect of increasing doses of metronidazole on the mean granuloma area expressed as a percentage of the area of the egg alone 16 days after intravenous injection of S. mansoni eggs into the pulmonary microvasculature of mice. unsensitized mice), a further experiment was performed. 30 mice were sen- days cf. 25,000 pmz (3,600- 57,000 pm2) in control mice. for sitized by the intraperitoneal injection of 1,500 eggs. Two tleeks later, groups of 10 Plastic Bead Granulomq Daily doses of metronidazole had no ef- fect on the inflammatory reaction around divinyl benzene copolymer beads 48 h after intravenous injection. The mean area of inflammation in eight control mice was 4,400 prm2 (range 800-11-,000). This value was not significantly different from the values of 3,600 (800-8,800) and 3,700 prm2 (600-7,600) for groups of eight mice given, respectively, 200 and 20 mglkg metronidazole daily. In order to determine whether this fail- Immunosuppression with Metronidazole 425 ure to suppress inflammation around beads mediated immunity. Its influence was most was due to the fact that metronidazole was administered for only 48 h (cf. 16 days for the egg granuloma in unsensitized mice), a further experiment was performed. Groups of ten mice were given either 20 or 200 mgl kg metronidazole daily for L6 days. On the 74th day, 3,000 beads were injected intravenously into these mice and into ten con- marked when given contemporaneously with exposure to antigen and administered trol mice. Again, no significant differences were found, the mean area of inflammation being 2,100 pm, (490-4,560 pm2) in mice given 20 mglkg metronidazole and L,970 p.m2 (640-4,340 pm2) in those given 200 mg/kg metronidazole, 2,720 prmz (600-4,390,r2m2) in control mice. cf. Delayed F ootpad Swelling Metronidazole 20 mgikg given daily sup- of delayed hyperin response to soluble schistosome egg antigen: control mice had a mean increase in footpad thickness of 360+23 p.m compared with 34+44 p.m in the treated group (p(0.001", pressed the development sensitivity footpad swellings Student's t test). S kin Allo gralt Surv iv al daily thereafter. A dose-response effect was demonstrated with the area of granulomatous inflammation around schistosome eggs decreasing with increasing doses of metronidazole. Under these circumstances, the suppression of granuloma formation around schistosome eggs was nearly as marked as In a preliminary experiment, mice given 20 mg/kg of metronidazole daily had 47010 suppression of granuloma formation compared with 690/o suppression in those given 100 mg/kg of niridazole daily. In contrast to niridazole [5], however, when metronidazole was given to mice which were previously sensitized to antigen, no significant suppression of the granulomatous reaction occurred. Similarly, the immunosuppressive action of metronidazole was not long-lived as there was no eftect L6 days after a single administration whereas a single dose of niridazole suppressed granuloma formation for more than 30 days [6]. That granuloma suppression is not a nonspecific, anti-inflammatory effect is indicated by the failure of metronidazole to affect the nonimmunological, chemically-mediated with niridazole. BALB/c J mice treated with metronidazole did not show any prolongation of allograft survival. Grafts survived 10.4+0.2 days in 13 control mice compared with 10.3+0.2 days in nine mice given 20 mg/kg daily and 10.6+0.2 days in 15 mice given The inhibition of delayed footpad reactions to soluble schistosome egg antigen is further evidence of the ability of metronidazole to suppress cell-mediated immunologi- 200 mglkg metronidazole on alternate days. cal reactions. The inability of the drug to Discussion Metronidazole appears to have selective immunosuppressive activity with inhibition of some, but not other, parameters of cell- plastic bead granuloma [4, 15]. suppress skin allograft rejection, even when given prior to grafting, suggests that the immunosuppressive action of this drug is selective. It must be noted, however, that 6-mercaptopurine, which is used widely in clinical organ transplantation, failed to pro- long skin allograft survival in mice 1l2l.It Grove/Mahmoud/Warren 426 is possible that these various reactions may be mediated by different subclasses of T lymphocytes perhaps with varying cooperation of macrophages. The immunosuppressive effects of metronidazole may be related to other phenomena which have been associated with this drug. The increased incidence of lung tumors and malignant lymphoma in mice given metronidazole may be the result of inhibition of tumor surveillance systems [1-0]. Similarly, the rapid resolution of inflammation seen in patieqts with dracunculiasis may, in part, reflect the irnmunosuppressive activity of metronidazole f1, 3]. Furthermore, metronidazole reportedly hastened the resolution of a variety of cutaneous ulcers, and it was suggested that this was due to an anti-inflammatory action [13]. A recent report has indicated that metronidazole may be beneficial in patients with Crohn's disease [1a]. In the absence of any known immunosuppressive action, these authors suggested that the drug may exert its effect by altering the bacterial flora of the gut. In view of the fact that Crohn's disease is characterized pathologically by granuloma formation, this beneficial response may be due in part, to an immunosuppressant effect of metronidazole. Further investigations of the anti-inflammatory and immunosuppressive properties of this drug may be fruitful. References 1 Antani, J.; Srinivas, H. V.; Krishnamurthy, K. R., and Boregaonkar, A. N.: Metronidazole in dracunculiasis. Report of further trials. Am. J. trop. Med. Hys. 21: t78-t9l (1972). 2 Boros, D. L. and Warren, K. S.: Delayed hypersensitivity-type granuloma formation and dermal reaction induced and elicited by a solu- ble factor isolated from Sc/zistosoma mansoni eggs. J. exp. Med. 132:4BB-507 (1970). A controlled field trial of the treatment of dracontiasis with metronidazole and niridazole. Ann. trop. Med. Parasit. 68.' 9r-9s (1974). 4 Kellermeyer, R, W. and Warren, K. S.: The role of chemical mediators in the inflammatory response induced by foreign bodies. Comparison with schistosome egg granuloma. J. 3 Kale, O. O.: exp. Med. 131:2L-38 (L970). 5 Mahmoud, A. A. F. and Warren, K. S.: Antlinflammatory effects of tartar emetic and niridazole. Suppression of schistosome egg granuloma. J. Immun. 112:222-228 (1974). 6 Mahmoud, A. A. F.; Mandel, M. A.; Warren, K. S., and Webster, L. T., jr.: Niridazole. II. A of cellular hypersensitivity. J. Immun. 1 I 4 : 27 9-283 (197 5). Moore, D. L.; Grove, D. I., and Warren, K. S.: The Schistosoma mansoni egg granuloma: potent long-acting suppressant 7 quantitation of cell populations. J. Path. 8 Raffier, G.: Activity of niridazole in dracontiasis. Ann. N. Y. Acad. Sci. 160; 720-728 (1e6e). L M.: in Goodman and Gilman, The pharrnacological basis of iherapeutics; 5th ed' (MacMillan, New York 1975). 10 Rustra, M. and Shubik, P.: Induction of lung tumors and malignant lymphomas in mice by 9 Rollo, metronidazole. Acknowledgements We gratefully acknowledge the expert technical assistance of Melanie Zuik, Earlene Moss and Pierre A. Peters. "fhese studies have been supported by a grant from NIH-PHS No. AI-08163 and grants from The Rockefeller and Edna McConnell Clark Foundations. (in press). J. natn. Cancer Inst. 48: 72r-729 (1972). 11 Sokal, R. R. and Rohlf, F. J.: Biometry. The principles and practice of statistics in biologi- cal research, p.253 (Freeman, New York 1969). 12 Stewart, P. B.: Failure of 6-mercaptopurine to prolong the survival of skin allografts in mice. Transplantation 7; 498-505 (1969). 13 Tanga, M. R,; Antani, J. A., and Kabade, S. Immunosuppression with Metronidazole 427 S.: Clinical evaluation of metronidazole as an anti-inflammatory agent. Int. Surg. 60: 75J6 persensitivity. Am. I. Path. 51: 735-:756 (L967). (1e7s). 14 Ursing, B. and Kamme, C.: Metronidazole for Crohn's disease. Lancet i.' 775-777 (L975). 15 Warren, K. S.: A functional classification of granulomatous inflammation, Ann. N. Acad. Sci. 278:7-L8 (1976). 16 Warren, K. S.; Domingo, E. O., and Received: November 15, 1977 Y. Cowan, R. B. T.: Granuloma formation around schistosome eggs as a manifestation of delayed hy- Correspondence to: Dr. David I. Grove, Division of Geographic Medicine, Wearn Research Building, University Hospitals, Cleveland, OH 44106 (USA)